Some of the known biomarkers (e.g. von hippel lindau, hypoxia-inducible factor, MET, and PDL1) in RCC were not significantly correlated with early relapse at the RNA level, because it is known that changes in DNA are not always reflected by differential RNA expression and that mutations related with tumor are not necessarily associated with clinical outcome27. This evidence concerns the gene CD274 and renal cell adenocarcinoma.